4548

SEIKAGAKU CORPORATION

生化学工業株式会社
Pharmaceutical
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. It also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, the company develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate used in artificial dialysis. Further, its products under development include SI-6603 for lumbar disc herniation; SI-614, a dry eye treatment; SI-613 for osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was incorporated in 1947 and is headquartered in Tokyo, Japan.
← Companies
Price
¥774
Market Cap
¥42.2B
Ent. Value
¥33.6B
Net Cash
¥8.6B
Shares Out.
54.6M
P / E
28.7×
EV / EBIT
⚠ TSE Capital Mandate
P / Book
0.56×
P / NCAV
1.43×
Div. Yield
1.94%
Financials
Metric FY 2025
TDnet
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Net Sales ¥36.6B ¥39.4B ¥36.2B ¥33.5B ¥34.9B
Cost of Sales ¥20.7B ¥20.2B ¥19.3B ¥15.4B ¥14.3B
Gross Profit ¥16.0B ¥19.2B ¥16.9B ¥18.0B ¥20.5B
SG&A ¥16.6B ¥17.8B ¥16.4B ¥15.9B ¥16.0B
Operating Income ¥-660M ¥1.3B ¥433M ¥2.1B ¥4.5B
Non-Operating Income ¥2.4B ¥891M ¥1.3B ¥967M ¥1.0B
Dividend Income ¥463M ¥391M ¥353M ¥358M
Interest Income ¥162M ¥150M ¥51M ¥28M
Non-Operating Expenses ¥291M ¥45M ¥12M ¥105M
Interest Expense ¥4M ¥4M ¥5M ¥11M
Ordinary Income ¥1.7B ¥1.9B ¥1.7B ¥3.1B ¥5.4B
Pre-tax Income ¥1.5B ¥1.9B ¥1.7B ¥3.1B ¥5.4B
Income Taxes ¥36M ¥718M ¥-495M ¥832M ¥1.7B
Current Tax ¥316M ¥151M ¥463M ¥769M
Deferred Tax ¥402M ¥-647M ¥369M ¥892M
Net Income (owners) ¥1.5B ¥1.2B ¥2.2B ¥2.2B ¥3.7B
Comprehensive Income ¥2.4B ¥6.5B ¥3.9B ¥4.6B
EBITDA ¥1.3B ¥3.3B ¥2.1B ¥3.4B ¥5.5B
Goodwill Amort. (J-GAAP) ¥193M ¥181M ¥176M ¥180M
EPS ¥26.99 ¥22.25 ¥40.08 ¥40.49 ¥66.32
Shares Outstanding 54.6M 54.6M 54.5M 56.2M
Shares Issued (total) 56.8M 56.8M 56.8M 56.8M
Treasury Shares 2.2M 2.3M 2.3M 0.6M